SABR patients were stable during the 12 months while surgical patients reported clinically significant deterioration at 6 weeks. Read more
Practical aspects of clinically managing operable SABR patients are important for the long-term care of this unique population. Read more
To increase access to radiotherapy worldwide, new guidance from the WHO and IAEA includes a prioritized list of medical devices for cancer management. Read more
Dr. Rodriguez de Dios talks with ILCN about the implications of the PREMER study, a phase III trial comparing PCI with and without hippocampal avoidance in SCLC. Read more
Spine metastases represent a common complication of lung cancer and other cancers, with approximately 40% of patients developing clinically significant spinal metastatic disease and up to 90% developing subclinical micrometastases. […] Read more
A leading cause of mortality worldwide, cancer was tied to nearly 10 million deaths in 2020.1 Lung cancer has remained unchallenged for more than 30 years as the most commonly […] Read more
A 65-year-old patient with stage III NSCLC comes to your clinic to discuss concurrent chemoradiotherapy. She has a history of ischemic heart disease, and 4 years ago an angiogram demonstrated […] Read more
Hippocampal-Sparing Brain Irradiation: The Future of Brain Metastases Treatment and Prevention?
+more
Brain metastases (BMs) are frequently diagnosed in patients with SCLC and NSCLC, although the incidence is highest in SCLC.1 ,2 ,3 BMs are a negative prognostic factor and are associated […] Read more
Prophylactic radiotherapy for the prevention of brain metastases (Table 1) has not been considered a standard practice outside of limited stage SCLC, particularly amid the surge and approval of novel […] Read more
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Con Side
+more
The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeti... Read more